Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
drugs
life sciences
national blog main
patisiran
3
×
akcea therapeutics
alnylam pharmaceuticals
boston
fda
inotersen
national top stories
new york blog main
new york top stories
onpattro
rna interference
san diego blog main
san diego top stories
tafamidis
acute hepatic porphyrias
akin akinc
aminolevulinic acid
anylam pharmaceuticals
barry greene
biotech
boston university
cardiomyopathy
dan ollendorf
givosiran
hereditary transthyretin amyloidosis
john berk
mary o'donnell
neuropathy
new york
paul matteis
pfizer
regeneron pharmaceuticals
san francisco blog main
san francisco top stories
What
ago
3
×
alnylam
fda
drug
medicine
patients
rna
akcea
amyloidosis
approval
approve
approved
attr
available
awaits
battle
biological
crossed
debilitating
decades
decision
discovered
disease
fingers
friday
genetic
historic
indicated
interference
medicines
nod
oks
pfizer
pharmaceuticals
quick
rare
rnai
second
seek
sets
Language
Current search:
ago
×
patisiran
×
@xconomy.com
4 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
